U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H13Cl3N2OS
Molecular Weight 387.7127
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIOCONAZOLE

SMILES

c1cc(c(cc1Cl)Cl)C(Cn2ccnc2)OCc3ccsc3Cl

InChI

InChIKey=QXHHHPZILQDDPS-UHFFFAOYSA-N
InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB01007 | http://reference.medscape.com/drug/vagistat-1-tioconazole-topical-343494 | https://www.drugs.com/cdi/tioconazole.html

Tioconazole is an antifungal medication of the imidazole class used to treat infections caused by a fungus or yeast. Tioconazole is a broad-spectrum imidazole antifungal agent that inhibits the growth of human pathogenic yeasts. Tioconazole exhibits fungicidal activity in vitro against Candida albicans, other species of the genus Candida, and against Torulopsis glabrata. Tioconazole prevents the growth and function of some fungal organisms by interfering with the production of substances needed to preserve the cell membrane. This drug is effective only for infections caused by fungal organisms. Tioconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Tioconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel. Side effects (for the women's formulas) may include temporary burning/irritation of the vaginal area, moderate drowsiness, headache similar to a sinus headache, hives, and upper respiratory infection.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TZ-3

Approved Use

Directions before using this product read the enclosed brochure and instructions on foil packet for complete directions and information adults and children 12 years and over: 1.Open the foil packet just before use and remove purple cap. 2.Insert entire contents of applicator into the vagina at bedtime. Throw applicator away after use. children under 12 years of age: ask a doctor, Do not use if sealed foil packet torn, open, or incompletely sealed. 1-DOSE TREATMENT TIOCONAZOLE OINTMENT 6.5% VAGINAL ANTIFUNGAL DIRECTIONS FOR USE Tear open foil packet just before using. It is best to use at bedtime. Remove applicator and plunger from packet. Applicator is prefilled with vaginal ointment. While firmly holding the purple-capped end of the applicator, push the tip of the plunger into the base of applicator. REMOVE PURPLE CAP from top of applicator with a pull-twist action. Insert the applicator Lie on your back with your knees bent. Gently insert applicator into the vagina as far as it will go comfortably. Push the plunger into the applicator until it will go no farther. Withdraw the applicator and plunger and dispose of it in the wastebasket. Do not flush. DO NOT USE TAMPONS while using this medicine. Use sanitary napkins instead. PLEASE READ EDUCATIONAL BROCHURE FOR ADDITIONAL INFORMATION. 4260000 P6 DISTRIBUTED BY PERRIGO ALLEGAN, MI 48010 U.S.A. Tioconazole_oint_fig1-01 Tioconazole_oint_fig2-01 Tioconazole_oint_fig3-01

Launch Date

4.14374396E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13 ng/mL
6 % single, vaginal
dose: 6 %
route of administration: Vaginal
experiment type: SINGLE
co-administered:
TIOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
150 ng × h/mL
6 % single, vaginal
dose: 6 %
route of administration: Vaginal
experiment type: SINGLE
co-administered:
TIOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 6.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 6.5 %, 1 times / day
Sources:
unhealthy, adult
n = 80
Health Status: unhealthy
Condition: vulvovaginal candidiasis
Age Group: adult
Sex: unknown
Population Size: 80
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative.
1979 Apr
Current and emerging azole antifungal agents.
1999 Jan
Patents

Patents

Sample Use Guides

Insert 1 applicatorful (5 g of 6.5% ointment) intravaginally qHS once
Route of Administration: Vaginal
In Vitro Use Guide
The compounds were dissolved in dimethyl formamnide, and water was added to give a final Tioconazole concentration of 1 mg/ml in 10% dimethyl formamide-water. From this solution, serial twofold dilutions of the compounds in water were incorporated into diagnostic sensitivity test agar over an appropriate concentration range (normally 100 mkg/ml down to 0.0 1mkg/ml). Organisms were inoculated onto the surface of the agar, using a multipoint inoculator (Denley Instruments) which delivers approximately 1 id of the fungal inoculum. Candida spp., Torulopsis glabtata, and Cryptococcus neofomnans were grown overnight at 37 C in brain heart infusion broth (Difco Laboratories). The concentration of cells in the culture was determined in a hemocytometer and then appropriately diluted in broth to10 cells per ml. MICs were read after incubation at 37 C for 48 h.
Name Type Language
TIOCONAZOLE
EP   INCI   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN   INCI  
Official Name English
TIOCONAZOLE [ORANGE BOOK]
Common Name English
VAGISTAT-1
Brand Name English
TIOCONAZOLE [VANDF]
Common Name English
TIOCONAZOLE [JAN]
Common Name English
NSC-759169
Code English
TIOCONAZOLE [INN]
Common Name English
TIOCONAZOLE [USP]
Common Name English
TIOCONAZOLE [USAN]
Common Name English
UK-20,349
Code English
TIOCONAZOLE [MI]
Common Name English
TIOCONAZOLE [MART.]
Common Name English
TIOCONAZOLE [EP MONOGRAPH]
Common Name English
VAGISTAT
Brand Name English
UK-20349
Code English
TIOCONAZOLE [USP-RS]
Common Name English
TIOCONAZOLE [INCI]
Common Name English
TIOCONAZOLE [WHO-DD]
Common Name English
TIOCONAZOLE [USP MONOGRAPH]
Common Name English
1H-IMIDAZOLE, 1-(2-((2-CHLORO-3-THIENYL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000008217
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
NCI_THESAURUS C514
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
WHO-VATC QD01AC07
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
WHO-ATC G01AF08
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
NDF-RT N0000175487
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
WHO-ATC D01AC07
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
WHO-VATC QG01AF08
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
Code System Code Type Description
MERCK INDEX
M10878
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY Merck Index
RXCUI
38298
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY RxNorm
LACTMED
Tioconazole
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
EVMPD
SUB11080MIG
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
DRUG BANK
DB01007
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
DRUG CENTRAL
2675
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
CAS
65899-73-2
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
WIKIPEDIA
TIOCONAZOLE
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
ECHA (EC/EINECS)
265-973-8
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
EPA CompTox
65899-73-2
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
USP_CATALOG
1667439
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY USP-RS
FDA UNII
S57Y5X1117
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
INN
4572
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
MESH
C020527
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
PUBCHEM
5482
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
NCI_THESAURUS
C29500
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200438
Created by admin on Fri Jun 25 21:04:30 UTC 2021 , Edited by admin on Fri Jun 25 21:04:30 UTC 2021
PRIMARY